Company intelligence / Profile preview
Blue Horizon International
New York, New York, United Statesbluehorizoninternational.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Commercial
01
Overview
BHI has safely performed more than 4,000 stem cell therapies. Their research shows their cellular products are safe and effective in improving symptoms related to chronic inflammation, spinal cord injury, stroke, and musculoskeletal disorders. The FDA has approved their IND application for a clinical study of cell therapy for acute ischemic stroke.
- Therapeutic areas
- CardiovascularRheumatologyImmunologyNeurology
- Modalities
- Stem cell therapiesRegenerative medicineImmunocancer therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Wuhan University Department of Medicine and their Biochemistry Institute
Beyond the preview
Go deeper on Blue Horizon International.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Blue Horizon International.